CD56 is a fundamental marker in the determination of human natural killer (NK) cell subsets. The degree of CD56 expression is ubiquitously used to define human NK cell maturation, functional, and tissue-specific subsets, yet a unifying implication for the degree of CD56 expression in NK cells remains elusive. Peripheral blood (PB)-NK cells are dichotomized into CD56 bright , which highly express CD56, and CD56 dim , which have lower CD56 expression. Classically, CD56
It has been shown that the interaction of CD56 with human fibroblast cells can promote the differentiation of CD56 bright to CD56 dim NK cells. 2 However, considering the importance and the extent of use of this marker in NK cell biology, relatively little is known about how downregulation of CD56 contributes to NK cell maturation, what role the degree of CD56 expression plays in contexts separate from NK cell maturation, and whether CD56 has an active functional role in mature NK cells. Moreover, while CD56 bright NK cells were classically considered immunoregulatory, evidence is emerging to suggest that CD56 bright NK cells also comprise the most highly cytotoxic of NK cell subsets, producing contradictory implications for CD56 brightness. Given this, we ask: is there a unifying implication for the degree of CD56 brightness across NK cells? Herein, we explore the wide-ranging functions of CD56 bright NK cells in order to determine a unified meaning for the degree of CD56 brightness and shed new light on the implications of CD56 brightness in NK cell biology.
In different settings, CD56 bright NK cells can have vastly divergent functions. In their most classic definition, they are immunoregulatory and play important regulatory roles in numerous contexts. A seminal study by Hanna et al. revealed that decidual NK cells (dNK), which are superbright for CD56 expression, play a critical role in tissue remodeling during pregnancy. 3 They demonstrated that noncytotoxic CD56 superbright dNK cells promote trophoblast invasion through secretion of IL-8 and IP-10, and support angiogenesis through secretion of VEGF and PLGF. In contrast to the classic anti-tumor and anti-viral functions induced by NK cell activation, receptor-mediated activation of dNK cells enhanced the secretion of these tissuemodeling factors, revealing a distinct activation-induced functional profile. Due to these tissue-remodeling capabilities, dNK cells in fact improved tumor growth and vascularization of trophoblast choriocarcinomas. 3 Indeed, regulatory mechanisms have important implications that also extend to NK cells in the context of cancer. In contrast to anti-tumor splenic NK cells, our group has demonstrated that tumor-associated murine NK cells have a less mature phenotype and exhibit reduced expression of activation receptors, perforin, and granzyme B. 4 Similarly, in humans, tumor-associated NK cells are enriched in the less mature CD56 bright subset and in many ways resemble dNK cells. The presence of CD56 bright cells within a tumor correlates with poor prognosis and reduced time to disease recurrence following therapy. 5, 6 In addition, Crome et al. demonstrated that CD56 + TILs have impaired anti-tumor cytotoxicity and negatively regulate T cell expansion, TNFα, and IFN-γ production. 5 The regulation of T cells by CD56
bright NK cells has also been reported to play an important role in the attenuation of autoimmune disease. For example, Bielekova et al. demonstrated that daclizumab therapy, a mAb against the IL-2Rα chain, exerted its therapeutic effects in patients with multiple sclerosis by inducing the expansion of CD56 bright NK cells. 7 The expansion of CD56 bright cells is correlated with reduced brain inflammation and reduced T cell populations. While regulatory CD56 bright NK cells are considered to have poor cytotoxicity against tumor targets, these CD56 bright NK cells inhibited the survival of activated autologous T cells through direct cytotoxicity. 7 Thus, in these studies, CD56 bright cells have a strong propensity for regulatory function in response to activation signals.
In contrast to their classic regulatory roles, recent evidence has demonstrated that in certain contexts, CD56 bright NK cells have the capacity for anti-viral and anti-tumor cytotoxicity, which plays an important role in driving responses to therapies. For instance, in patients with chronic hepatitis B infection, Pegylated InterferonAlpha (PegIFNα) therapy induced preferential expansion of CD56 bright NK cells compared to CD56 dim cells. PegIFNα treatment enhanced the expression of activation receptors, degranulation, and IFN-γ production in CD56 bright NK cells. Importantly, this increase in degranulation and IFN-γ was only observed in patients who responded to therapy and was not observed in nonresponders. 8 While CD56 bright NK cells are typically considered to have poor cytotoxicity against tumor cells, a recent study demonstrated that IL-15-priming enhanced degranulation and cytotoxicity of CD56 bright PB-NK cells against tumor cells to levels that surpassed even those of IL-15-primed CD56 dim NK cells. In fact, these CD56 bright NK cells had a more comprehensive antitumor functional profile as they combined a superior ability to secrete high levels of IFN-γ with enhanced cytotoxic function. 9 Similarly, in the clinical setting, IL-15 infusion in cancer patients was shown to predominantly impact CD56 bright NK cells. IL-15 infusion induced greater expansion of CD56 bright NK cells and these expanded CD56 bright cells upregulated anti-tumor cytokine secretion and displayed strong anti-tumor cytotoxicity. 10 Ex vivo expansion of NK cells has also been shown to induce the growth of a highly cytotoxic CD56 bright NK cell subset. Indeed, following expansion with K562 feeder cells that express 4-1BBL and membrane-bound (mb)IL-21, the majority of the expanded NK cell population consisted of CD56 superbright cells, again with a combined capacity for high levels of anti-tumor cytokine production and cytotoxicity. 11 An important question arises in light of these disparate functions: is there a unifying implication for CD56 brightness in NK cells? If we place NK cell functional potential on a spectrum from regulatory and homeostatic to proinflammatory and cytotoxic, CD56 superbright NK cells seem to occupy the very far ends of this spectrum (Fig. 1) . In contrast, CD56 dim NK cells typically fit within the proinflammatory and cytotoxic section, but given the superior cytotoxic potential of CD56 bright NK cells that has recently been demonstrated, we suggest that the cytotoxic potential of CD56 dim NK cells does not reach that of CD56 bright . Thus, we propose that the brightness of CD56 in NK cells indicates a heightened potential for activation and function in both regulatory and proinflammatory contexts. To further explore this theory, we stratified mbIL-21 expanded NK cells based on the degree of CD56 expression into CD56 dim , CD56 bright , and CD56 superbright subsets. In support of our hypothesis, expanded NK cells had a specific increase in expression of activation receptors, IFN-γ, and degranulation in response to tumor targets with increasing CD56 expression, whereas expression of inhibitory receptors did not change with CD56 brightness. 11 This demonstrates that in the context of cytotoxic expanded NK cells, the degree of CD56 expression corresponds to heightened activation and anti-tumor functions. Moreover, this indicates that considering CD56 expression as a spectrum, rather than dichotomized subsets, can reveal further relationships between CD56 expression and NK cell function. Future exploration into whether the degree of CD56 expression within CD56 bright regulatory NK cells corresponds to enhanced regulatory function would address whether this concept holds true in the context of regulatory CD56 bright NK cells. While assessing NK cell function with respect to the degree of CD56 brightness has demonstrated that these two aspects are associated, it does not address another important question: does the degree of CD56 expression have an active role in regulating NK cell activation potential, or is it strictly a surrogate marker with expression that changes as a result of changes to activation potential? Knockdown of CD56 expression in CD56 bright NK cells would be instrumental in addressing this question.
NK cells play important roles in homeostasis, disease, and many emerging therapies for a variety of diseases that function by modulating NK cells. Furthermore, it is becoming increasingly apparent that specific NK cell subsets are responsible for the respective therapeutic responses. Given that the degree of CD56 brightness is integral to defining human NK cell subsets, determining what the CD56 brightness inherently represents across all NK cells would further our understanding of the functional potential of different NK cell subsets. This knowledge would lead to better identification of which subsets should be therapeutically targeted. Furthermore, it would facilitate efficient harnessing of specific subsets, potentially even by directly modulating CD56 expression, to improve therapeutic responses. If it holds true that increased CD56 expression corresponds to heightened activation and functional potential in both regulatory and cytotoxic contexts, this indicates that subsets with the highest CD56 expression hold profound potential for therapeutic modulation. superbright NK cells occupy the far ends of the NK cell functional spectrum. Schematic illustrating the concept that increasing CD56 brightness in NK cells corresponds to an increased potential for activation and function in both proinflammatory and regulatory contexts
